Haematology 2018

Lenalidomide

• Immunomodulatory properties

• Modulation of both cellular and cytokine tumour cell microenvironment • Activates T cell and NK response to tumour cell • Down regulates pro-survival cytokines • Enhanced ADCC activity with rituximab

Chanan-Khan, A. A. et al. J Clin Oncol; 26:1544-1552 2008